Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 17

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 17
---
 pay dividends in the future would be at the discretion of our Board of Directors and will depend upon our results of
operations, cash requirements, financial condition, contractual restrictions, and any future debt agreements and is subject to compliance
with applicable laws, including the United Kingdom Companies Act of 2006, or the Companies Act, which requires English companies to have
profits available for distribution equal to or greater than the amount of the proposed dividend.

| 11 |

<div align='center'>CAPITALIZATION</div>

The following table sets
forth our capitalization as of June 30, 2025. The information in this table is unaudited and should be read in conjunction with our consolidated unaudited interim financial statements and notes thereto and other financial information incorporated by reference into this prospectus.

| (£ in thousands)          |     | As of June 
 30, 2025   |        |
|:--------------------------|:----|:-----------|-------:|
| Cash and cash equivalents |     |            |  4,036 |
| Long-term debt            |     |            |     -- |
| Total equity              |     |            | 11,436 |
| Total capitalization      |     |            | 11,436 |

The table above does not include, as of June
30, 2025:

| · | 313,070,788                                                                              
 Ordinary Shares issuable upon the exercise of stock options outstanding under our equity 
 incentive plans at a weighted-average exercise price of £0.005                           
 per share;                                                                               |

| · | six                                                                                                
 Ordinary Shares issuable upon exercise of stock options assumed in connection with the acquisition 
 of DARA Biosciences, Inc., or DARA, in 2015 at a weighted average exercise price of $981.91;       
 and                                                                                                |

| · | warrants,                                                                                           
 including pre-funded warrants, exercisable for 48,848 Depositary Shares (representing 4,884,800,000 
 Ordinary Shares), at a weighted average exercise price of $402.20 per Depositary Share.             |

| 12 |

<div align='center'>SELLING SHAREHOLDERS</div>

This prospectus covers
the possible resale from time to time by the selling shareholders identified in the table below of Ordinary Shares represented by Depositary
Shares issuable upon the exercise of the December 2023 Private Placement Pre-Funded Warrants (referred to in this section collectively
and individually as the “warrants”).